H.R. 9547
Veterans and Servicemembers PTSD Emerging Treatment Review Act of 2026
Updated Aug 4, 2026, 4:07 AM ET
- Cosponsor Dan Crenshaw (R-TX)
- Cosponsor Seth Moulton (D-MA)
- Cosponsor Jennifer Kiggans (R-VA)
Bipartisan Not enacted
H.R. 9547
Updated Aug 4, 2026, 4:07 AM ET
Bipartisan Not enacted
(c) Elements The report under subsection (b) shall include the following:
(1) A summary of the safety, dosing, and adverse event data from the covered clinical trial that has been reviewed by any relevant department or agency of the Federal Government, or that is otherwise available to the Department of Defense, and an analysis by the Department of Defense of the applicability of such data to members of the Armed Forces.
(2) An assessment of the implications of such data for force health protection, medical readiness, and suicide prevention strategies, including identification of any gaps in existing treatment options for members of the Armed Forces with treatment-resistant post-traumatic stress disorder.
(3) A description of the legal and regulatory requirements for any potential expanded access pathway involving an investigational Schedule I substance, including coordination requirements with the Food and Drug Administration and the Drug Enforcement Administration.
(4) An assessment of the applicability of the Federal right to try the pathway under section 561B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–0a) and under Executive Order No. 14401 (91 Fed. Reg. 21709; relating to accelerating medical treatments for serious mental illness) the for treatment-resistant post-traumatic stress disorder and associated comorbidities, including elevated suicide risk during post-deployment and transition periods.
(5) An assessment of considerations necessary to ensure continuity of care for members of the Armed Forces transitioning from receiving health care at military medical treatment facilities to receiving health care furnished by the Veterans Health Administration, including—
(A) eligibility criteria;
(B) clinical treatment oversight;
(C) informed consent procedures;
(D) safety monitoring; and
(E) adverse event reporting.
(6) An assessment of the financial resources, workforce, and infrastructure requirements, and a proposed timeline, for any potential pilot activities or expanded clinical research beginning in fiscal year 2027, and for any broader implementation occurring thereafter, as appropriate.
(d) Coordination and consultation The Assistant Secretary of Defense for Health Affairs shall develop the report under subsection (b) in coordination with the Director of the Defense Health Agency and in consultation with the Secretary of Veterans Affairs, the Secretary of Health and Human Services, the Commissioner of Food and Drugs, and the heads of other departments and agencies of the Federal Government the Assistant Secretary determines appropriate.
(e) Form The report required under subsection (b) shall be submitted in unclassified form, but may include a classified annex if necessary.